Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07208136
PHASE1

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors

Sponsor: Jemincare

View on ClinicalTrials.gov

Summary

This is a first-in-human, Phase I, open-label, multi-center, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JMKX005425 in subjects with microsatellite instability-high (MSI) and/or mismatch repair deficiency (dMMR) advanced solid tumors.

Official title: An Open-label, Multi-center Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JMKX005425 Tablets in Subjects With Microsatellite Instability-High or Mismatch Repair Deficient Advanced Solid Tumors

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

102

Start Date

2025-10-22

Completion Date

2028-12

Last Updated

2025-12-01

Healthy Volunteers

No

Interventions

DRUG

JMKX005425

JMKX005425 administered orally.

Locations (1)

Beijing Cancer Hospital

Beijing, China